Executioner caspases 3 and 7 are dispensable for intestinal epithelium turnover and homeostasis at steady state – pnas.org

Significance Historically, programmed cell death by apoptosis is considered crucial for proper intestinal organogenesis and gut homeostasis. To challenge this concept, we generated caspase-3 and -7 double knockout mice specifically in intestinal epithelial cells (IECs). However, absence of apoptosis in IECs elicits neither morphological and inflammatory changes nor intestinal dysbiosis during gut homeostasis at steady state.

Read more
Gene therapy may be a curative treatment option for patients with transfusion-dependent beta-thalassemia – News-Medical.Net

A novel gene therapy promoted transfusion independence in more than 90 percent of adult and pediatric patients with transfusion-dependent beta-thalassemia, according to a recent clinical trial published in The New England Journal of Medicine. The therapy represents a potentially curative treatment option for patients who must otherwise rely on life-long red blood cell transfusions. This approach provides a potential cure for patients with transfusion dependent beta-thalassemia without the need for an allogeneic donor, and these extremely encouraging results will give hope to patients otherwise not eligible for cure of their disease." Jennifer Schneiderman, MD, '06 MS, associate professor of Pediatrics in the Division of Hematology, Oncology and Stem Cell Transplantation and co-author of the study Alexis Thompson, MD, MPH, former section chief of Hematology in the Department of Pediatrics and associate director for Equity and Minority Health at the Robert H.

Read more
BioRestorative Therapies Named One of Ten Most Innovative – GlobeNewswire

MELVILLE, N.Y., Jan. 26, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the Company" or BioRestorative) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced that it has been named by Insights Care Magazine as one of the ten most innovative regenerative medicine companies in 2022 for its work in developing novel cell-based therapeutics.

Read more